Pharmaceutical and diagnostic company Prometheus Laboratories has granted an oncology programme to Clinipace Worldwide, a global digital research organization (dCRO). As part of the contract, Clinipace Worldwide will study Proleukin ...
Tags: medical research, data management platform, clinical trial
The SFJ Pharmaceuticals Group (SFJ) has partnered with Pfizer to co-develop Dacomitinib as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of epidermal ...
Tags: Cancer Drug, cell lung cancer, therapy
Sagent Pharmaceuticals, a specialty pharmaceutical company, has introduced Irinotecan injection in two latex free, preservative free single dose vials. The antineoplastic agent of the topoisomerase I inhibitor class, in combination with ...
Aegis Therapeutics has received US patent covering pharmaceutical composition of octreotide. The octreotide formulations incorporate Aegis' Intravail/ProTek excipients suitable for all routes of administration including oral, buccal, ...
Tags: Octreotide Formulations, Aegis Therapeutics, polysorbate surfactants
Celgene International Sàrl Abraxane, an albumin-bound form of paclitaxel, has demonstrated statistically significant improvementin overall survival for advanced pancreatic cancer patients in Phase III study. The Metastatic ...
Eli Lilly and Company Alimta(pemetrexed for injection)has received FDA approval for new use in the continuation maintenance setting for advanced or metastatic nonsquamous non-small cell lung cancer(NS NSCLC). The approval was based on ...
Jennerex has treated the first patient in a Phase 2 clinical trial of intravenous treatment with JX-594 for patients with advanced hepatocellular carcinoma(HCC)who have not received treatment with sorafeni. The ...
Tags: hepatocellular carcinoma, JX-594, intravenous treatment, Jennerex
Janssen Research and Development has received the Priority Review for the supplemental New Drug Application (sNDA) for ZYTIGA from US Food and Drug Administration (FDA). Zytiga (abiraterone acetate) is administered in combination with ...
Tags: sNDA, priority review, FDA
The US Food and Drug Administration (FDA) has approved ZALTRAP (ziv-aflibercept) injection to be used in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) to treat patients with metastatic colorectal cancer (mCRC) that is ...
Tags: Zaltrap Injection, Medicine
The US Patent and Trademark Office (USPTO) has granted patent No. 8,232,262 to Ziopharm Oncology's palifosfamide (ZIO-201). The patent covers palifosfamide compositions, formulations, methods of use and methods of manufacture, which now ...
Tags: USPTO, patent, Palifosfamide, cancer treatment drug
The USFDA has accepted Exelixis' new drug application for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer and granted priority review designation. ...
Tags: FDA, new drug application, Priority Review Designation
inVentiv Medical Management, a provider of medical management services, has formed strategic alliance with Vital Decisions to better serve the needs of payers, providers, and seriously ill patients. Under the alliance, iMM and Vital ...
Tags: medical management services, care management and counseling program
The US FDA has granted priority review designation to Bayer HealthCare's new drug application (NDA) filed for regorafenib to treat patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard ...
Tags: US FDA, Bayer HealthCare, NDA
Astellas Pharma and Medivation have announced the submission of marketing authorization application (MAA) to the European Medicines Agency (EMA) for enzalutamide to treat metastatic castration-resistant prostate cancer in men who have ...
Tags: enzalutamide, metastatic castration-resistant prostate cancer
Janssen Research & Development has announced that it has submitted a supplemental New Drug Application to FDA for ZYTIGA(abiraterone acetate). Janssen-Cilag International NV has also sent a type II variation to the European Medicines ...